107.15
1.35 (1.28%)
| Previous Close | 105.80 |
| Volume | 3,822,379 |
| Price / Earnings (Forward) | 31.24 |
| Price / Sales | 9.30 |
| Price / Book | 5.68 |
| 52 Weeks Range |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
News Mood
AIStockmoo Score
| Value 30% | 0.5 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| The price implies earnings growth of 24.4% a year; the business can fund about 15.0% a year. info | |
| Valuation History info | NA |
| Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | 2.9 |
| From our AI technical analysis of the chart. info | NA |
| No clear trend over the past year. Trading near its 52-week high. info | |
| Recent bearish reversal pattern: Dark cloud cover. info | |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.7 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 0.6 |
| No clear net insider buying or selling. info | |
| Institutions net +0.94% of shares in their latest 13F filings: 606 holders increased, 629 decreased (quarter to 30 Sep 2026). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Levels trending up. info | |
| Final Score | 1.42 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| EW | - | - | - | 5.68 |
| SNN | - | 2.04% | - | 2.55 |
| SYK | - | 1.05% | - | 5.07 |
| BSX | - | - | - | 2.51 |
| ABT | - | 1.85% | - | 3.68 |
| PHG | - | 3.48% | - | 2.24 |
Select this tab to load the latest available analysis.
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOBO DONALD E JR | - | 104.71 | -48,900 | -5,120,319 |
| LIPPIS DANIEL J. | - | 104.01 | -619 | -64,382 |
| ZOVIGHIAN BERNARD J | - | 104.71 | -23,100 | -2,418,801 |
| Aggregate Net Quantity | -72,619 | |||
| Aggregate Net Value ($) | -7,603,502 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 104.70 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIPPIS DANIEL J. | Officer | 10 Nov 2026 | Automatic sell (-) | 619 | 104.01 | 64,382 |
| LIPPIS DANIEL J. | Officer | 10 Nov 2026 | Option execute | 619 | - | - |
| BOBO DONALD E JR | Officer | 09 Nov 2026 | Automatic sell (-) | 48,900 | 104.71 | 5,120,319 |
| BOBO DONALD E JR | Officer | 09 Nov 2026 | Option execute | 48,900 | - | - |
| ZOVIGHIAN BERNARD J | Officer | 09 Nov 2026 | Automatic sell (-) | 23,100 | 104.71 | 2,418,801 |
| ZOVIGHIAN BERNARD J | Officer | 09 Nov 2026 | Option execute | 23,100 | - | - |
Institutions
Institutional ownership: 103.07%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 606 | 51,369,747 |
| Decreased | 629 | 50,223,039 |
| New | 125 | 13,031,498 |
| Sold out | 105 | 8,790,947 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Is There Any Reason To Invest In Edwards Lifesciences Stock?
For questions about this article or underlying research, email [email protected]. |
| 13 Nov 2026 | Yahoo Finance |
A $9.2 Billion Fund Dumps These 3 Stocks
Key TakeawaysA fund with $9. 2 billion in US stocks sold all of its Edwards Lifesciences, PepsiCo and ServiceNow shares in the third quarter, about a tenth of its portfolio at June 30… |
| 07 Nov 2026 | Yahoo Finance |
Edwards Lifesciences Q3 Earnings Call Highlights
Edwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations, with growth across its heart-valve businesses and regions. The medical device maker reported sales of $1.72 billion, up 11.2% from a year earlier, and adjusted… |
| 05 Nov 2026 | Yahoo Finance |
Edwards Life (EW) Q3 2026 Earnings Call Transcript
Edwards raised its sales outlook after a quarter that beat internal projections. |
| 05 Nov 2026 | Yahoo Finance |
CAH Shares Post New Record, EW Stock Hits Over Three-Year High – What’s Driving Today’s Rally?
Cardinal Health reported a 5% increase in Q1 revenue, beating Wall Street’s forecast, while analysts raised Edwards Lifesciences’ price target after a better-than-expected Q3 print. |
| 05 Nov 2026 | Yahoo Finance |
Edwards Lifesciences Corp (EW) (Q3 2026) Earnings Call Highlights: Broad-Based TAVR and TMTT ...
Edwards Lifesciences Corp (EW) posted 11.2% sales growth to $1.72 billion and lifted full-year adjusted EPS guidance to $2.97--$3.05, as TMTT surged 45.6% and TAVR grew 8.8%. |
| 05 Nov 2026 | Yahoo Finance |
Edwards bumps up sales forecast on TAVR strength in Q3
Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement. |
| 05 Nov 2026 | Yahoo Finance |
Edwards Lifesciences (EW) Trial Data Points To Earlier TAVR Use In Moderate Aortic Stenosis
Edwards Lifesciences (NYSE:EW) reported new PROGRESS Trial data showing transcatheter aortic valve replacement outperformed active surveillance in moderate aortic stenosis. The trial linked TAVR use in moderate aortic stenosis with fewer combined outcomes of death or heart failure events in at-risk… |
| 05 Nov 2026 | Yahoo Finance |
Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance. |
| 04 Nov 2026 | Yahoo Finance |
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif., November 04, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026… |
| 04 Nov 2026 | Yahoo Finance |
Edwards Lifesciences (EW) Trial Win Puts Fair Value Back In Focus
Edwards Lifesciences (EW) is back in focus after new data showed its PASCAL tricuspid repair system outperformed medical therapy in the CLASP II TR trial, with benefits sustained through one year. Recent data and regulatory milestones have come alongside clear momentum in the Edwards Lifesciences… |
| 03 Nov 2026 | Yahoo Finance |
Edwards Lifesciences' Progress Data Unlikely to Expand TAVR Market, RBC Says
Edwards Lifesciences' (EW) Progress trial is unlikely to meaningfully expand the market for transcat… |
| 02 Nov 2026 | Yahoo Finance |
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
Edwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic st… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |